NRx Pharma

NRx Pharma The U.S.

We are NRx – a pioneering and focused CNS biopharma company, dedicated to meeting unmet medical needs for those with suicidal depression, suicidal bipolar depression, and post-traumatic stress disorder (PTSD). Food and Drug Administration (“FDA”) has additionally granted Breakthrough Therapy designation, a Special Protocol Agreement, and a Biomarker Letter of Support for NRX-101, an investigational medicine for the treatment of severe bipolar depression in patients with acute suicidal ideation and behavior (ASIB) after initial stabilization with ketamine or other effective therapy. NRx Pharmaceuticals is led by executives who have held leadership roles at Lilly, Pfizer, and Novartis as well as major investment banking institutions.

02/27/2026

🧬 NRX-101: A Novel Oral Therapy for CNS Care

’s NRX-101 is a patented oral therapy that combines two FDA-approved drugs: D-cycloserine, which modulates NMDA receptor activity at defined doses, and lurasidone, a 5-HT2A receptor antagonist, designed to address serious unmet needs in mental health care.

Science-driven innovation with real-world impact.

Watch the interview here👇🏻
https://bit.ly/NTTS-RxPharmaAdvancesPTSDandDepressionTreatment

👉🏻Learn more at https://bit.ly/NRXPharmaceuticals

Our CEO Dr. Jonathan Javitt was honored to be an invited guest in the House Chamber at this year's State of the Union ad...
02/25/2026

Our CEO Dr. Jonathan Javitt was honored to be an invited guest in the House Chamber at this year's State of the Union address.

“It is amazing to have an Administration and a Legislature aligned on the need for neuroplastic therapies to treat suicidal depression and PTSD. We are seeing the results in our HOPE Therapeutics Clinics every day.”

$NRXP

02/24/2026

🧪 NRx Pharmaceuticals Advances NRX-100 Toward NDA

(NASDAQ: NRXP) announced a clear path to a New Drug Application supported by real-world data and a broader proposed indication for NRX-100 (ketamine) following a Type C meeting with the U.S. Food and Drug Administration.**

A key step forward in expanding treatment options for patients with critical unmet needs.

READ HERE👇🏻
https://bit.ly/NRXpressrelease

Check out the latest NewsOut update here👇🏻
https://bit.ly/NTTS-NEWSOUT-NRXPharmaAdvancesKetamineTherapyTowardFDAFilingforSevereDepression

Watch the interview here👇🏻
https://bit.ly/NTTS-RxPharmaAdvancesPTSDandDepressionTreatment

👉🏻Learn more at https://bit.ly/NRXPharmaceuticals

FDA Meeting Indicates Path to New Drug Application with Real World Data and Broader Indication of NRX-100 (Ketamine) for...
02/23/2026

FDA Meeting Indicates Path to New Drug Application with Real World Data and Broader Indication of NRX-100 (Ketamine) for Suicidal Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - Boston Herald

Read More - https://markets.financialcontent.com/bostonherald/article/getnews-2026-2-17-fda-meeting-indicates-path-to-new-drug-application-with-real-world-data-and-broader-indication-of-nrx-100-ketamine-for-suicidal-depression-nrx-pharmaceuticals-inc-nasdaq-nrxp/

$NRXP

Boston news, sports, politics, opinion, entertainment, weather and obituaries

FDA Meeting Indicates Path to New Drug Application with Real World Data and Broader Indication of NRX-100 (Ketamine) for...
02/18/2026

FDA Meeting Indicates Path to New Drug Application with Real World Data and Broader Indication of NRX-100 (Ketamine) for Suicidal Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - APnews

Read More - https://apnews.com/press-release/getnews/fda-meeting-indicates-path-to-new-drug-application-with-real-world-data-and-broader-indication-of-nrx-100-ketamine-for-suicidal-depression-nrx-pharmaceuticals-inc-nasdaq-nrxp-dd71711c89cf28af312f92febcd62cc4

$NRXP

$NRXP Also Entered Joint Offering with and neurocare Group for Neuroplastic Therapy Targeting Depression, PTSD and Other Mental Health Afflictions

Milestone Patient Data Eclipsing 70,000 on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitt...
02/09/2026

Milestone Patient Data Eclipsing 70,000 on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) -Wall Street Select

$NRXP

Milestone Patient Data Eclipsing 70,000 on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

Dr. Jonathan Javitt, MD, MPH, Founder, Chairman, and Chief Scientist of NRx Pharmaceuticals interview at NobleCon21 – No...
02/02/2026

Dr. Jonathan Javitt, MD, MPH, Founder, Chairman, and Chief Scientist of NRx Pharmaceuticals interview at NobleCon21 – Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference

https://youtu.be/zDs0lrsJ_G0

$NRXP

Visit RedChip.com to learn more.

Address

1201 N Market Street, Suite 111
Wilmington, DE
19801

Website

Alerts

Be the first to know and let us send you an email when NRx Pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category